Keitaro Shimozaki

10PUBLICATIONS
19CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 16, 2026
Increased treatment options and improved survival in real-world patients with HER2-positive advanced gastric cancer from 2011 to 2023.

|Dec 18, 2025
Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience.

Keitaro Shimozaki, Akira Ooki, Shota Fukuoka

|Feb 27, 2025
Investigating the role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011 and 2023.

Keitaro Shimozaki, Akira Ooki, Koichiro Yoshino

|Nov 06, 2023
Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study.

Keitaro Shimozaki, Izuma Nakayama, Daisuke Takahari

|Apr 13, 2023
Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era.

Keitaro Shimozaki, Izuma Nakayama, Toru Hirota

|Apr 19, 2022
KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer.

Keitaro Shimozaki, Eiji Shinozaki, Noriko Yamamoto

Pageof 2

Frequent Collaborators

4 joint publications

Akira Ooki

2 joint publications

Hideyuki Hayashi

2 joint publications

Yasuo Hamamoto

2 joint publications

Eiji Shinozaki